个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ ESCI

作者：
Hong, Bu[1] ; Ying, Fan[2] ; Zhaoqing, Fan[3] ; Xichun, Hu[4,10] ; Man, Li[5] ; Qiao, Li[2] ; Ning, Liao[6] ; Ting, Luo[7] ; Jianyun, Nie[8] ; Yueyin, Pan[9] ; Xiaowei, Qi[1,10] ; Zhimin, Shao[1,11] ; Guohong, Song[1,2,12] ; Tao, Sun[1,3,13] ; Yue-e, Teng[1,4,14] ; Zhongsheng, Tong[1,5,15] ; Jiayu, Wang[2] ; Shusen, Wang[1,6,16] ; Xue, Wang[1,7,17] ; Yongsheng, Wang[1,8,18] ; Zhonghua, Wang[1] ; Binghe, Xu[1,19] ; Ling, Xu[2,20] ; Yan, Xue[21] ; Wentao, Yang[22] ; Herui, Yao[23] ; Jianning, Ying[24] ; Peng, Yuan[11] ; Jian, Zhang[4,10] ; Qingyuan, Zhan[25] ; Yongqiang, Zhang[26] ; Jiuda, Zhao[4,27] ;
机构： [1]Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China [2]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Dept Internal Med,Canc Hosp, Beijing, Peoples R China [3]Peking Univ Canc Hosp & Inst, Breast Canc Prevent & Treatment Ctr, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China [4]Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Shanghai, Peoples R China [5]Second Hosp Dalian Med Univ, Dept Cardiology2, Dalian, Peoples R China [6]Guangdong Prov Peoples Hosp, Dept Breast Canc, Ctr Canc, Guangzhou, Peoples R China [7]Sichuan Univ, West China Hosp, Breast Dis Ctr, Chengdu, Peoples R China [8]Kunming Med Univ, Yunnan Canc Hosp, Dept Breast Surg, Affiliated Hosp 3, Kunming, Peoples R China [9]First Affiliated Hosp USTC, Anhui Prov Hosp, Dept Hematol, Hefei 230001, Peoples R China [10]Chongqing Gen Hosp, Dept Breast & Thyroid Surg, Chongqing, Peoples R China [11]Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai, Peoples R China [12]Peking Univ Canc Hosp & Inst, Dept Breast Oncol, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China [13]Liaoning Canc Hosp & Inst, Dept Breast Surg, Shenyang 110042, Liaoning, Peoples R China [14]First Hosp China Med Univ, Dept Radiol, Shenyang, Peoples R China [15]Tianjin Med Univ Canc Inst & Hosp, Dept Breast Med, Tianjin, Peoples R China [16]Sun Yat Sen Univ, Canc Ctr, Dept Hematol Oncol, Guangzhou, Peoples R China [17]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept VIP Med Serv,Canc Hosp, Beijing, Peoples R China [18]Shandong Canc Hosp, Breast Canc Ctr, Jinan, Shandong, Peoples R China [19]Chinese Acad Med Sci & Peking Union Med Coll, Clin Trial Ctr, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China [20]Peking Univ First Hosp, Breast Dis Ctr, Beijing, Peoples R China [21]Xian Int Med Ctr Hosp, Dept Oncol, Xian, Peoples R China [22]Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai, Peoples R China [23]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Oncol, Guangzhou, Peoples R China [24]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Pathol,Canc Hosp, Beijing, Peoples R China [25]Harbin Med Univ, Canc Hosp, Dept Oncol, Harbin, Peoples R China [26]Beijing Hosp, Dept Pathol, Beijing, Peoples R China [27]Qinghai Univ, Breast Dis Diag & Treatment Ctr, Affiliated Hosp, Xining 810000, Peoples R China
出处：
DOI： 10.1016/j.jncc.2023.09.002

关键词： Breast cancer HER2-low Antibody -drug conjugate

摘要：
Treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER2; HER2low) has drawn much attention in recent years. With the proven therapeutic effect of trastuzumab deruxtecan (T-DXd) in patients with HER2-low (immunohistochemistry [IHC] 1 + , or IHC2 + /in situ hybridization [ISH]-) breast cancer, HER2-low may become a new subtype of targeted therapy for breast cancer. The expert committee formulated this consensus based on the current clinical studies and clinical medication experience. The currentconsensus is the collaborative work of an interdisciplinary working group, including experts in the fields of pathology and oncology. The purpose of this consensus was to guide the clinical diagnosis and treatment of HER2-low breast cancer, thereby prolonging the overall survival of patients.

语种：
外文
被引次数：
WOS：
PubmedID：
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China
通讯作者：
通讯机构： [1]Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China [19]Chinese Acad Med Sci & Peking Union Med Coll, Clin Trial Ctr, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Hong Bu,Ying Fan,Zhaoqing Fan,et al.Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)[J].Journal Of The National Cancer Center.2023,3(4):266-272.doi:10.1016/j.jncc.2023.09.002.
APA：
Hong, Bu,Ying, Fan,Zhaoqing, Fan,Xichun, Hu,Man, Li...&Jiuda, Zhao.(2023).Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition).Journal Of The National Cancer Center,3,(4)
MLA：
Hong, Bu,et al."Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)".Journal Of The National Cancer Center 3..4(2023):266-272

相关文献

[1]A Study YL201 in Patients With Selected Advanced Solid Tumors [2]A Study of YL202 in Selected Patients With Advanced Solid Tumors [3]Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer [4]Antibody-drug conjugates targeting DDR1 as a novel strategy for treatment of breast cancer [5]Unfavorable Prognostic Impact of HER2 2+/FISH-Negativity in Older Patients with HER2-Negative and High-Risk Breast Cancer [6]DOG1 as a novel antibody-drug conjugate target for the treatment of multiple gastrointestinal tumors and liver metastasis [7]Design, Synthesis, and Bioevaluation of a Novel Hybrid Molecular Pyrrolobenzodiazepine-Anthracenecarboxyimide as a Payload for Antibody-Drug Conjugate [8]Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer [9]A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent therapeutic efficacy in gastrointestinal tumor xenograft models. [10]Open-label, multicenter, phase 2 study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma.

资源点击量：52808 今日访问量：2 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号